Net Present Value Model: Gamunex/Gamimune N
Powered by
Unlock hidden opportunities in the NPV industry
Overview
Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis.
Drug Operating Profit Model
Gamunex/Gamimune N Drug Details
Human Immunoglobulin G (also known as human normal immunoglobulin) (Flebogamma DIF/Gamimune N/Gammaked/ Gamunex C/ Flebogamma/ IGIVnex/ GamaSTAN S/D/ Gamunex/ Igamplia/ Plangamma/ Polyglobin/ GamaSTAN, Plitagamma) is an antibody preparation derived from plasma acts as passive immunizing preparation. It is formulated as solution for intramuscular or subcutaneous route of administration. Flebogamma DIF (Double Inactivation and Filtration) and Gamunex is used for replacement therapy in patients with primary immunodeficiency syndromes with impaired antibody production and for hypogammaglobulinemia in various pathological conditions. They also used for the treatment of primary immune thrombocytopenia (ITP), Guillain Barre syndrome and Kawasaki disease. Gamunex-C [Caprylate/Chromatography Purified] is used for the Primary Humoral Immunodeficiency, Idiopathic Thrombocytopenic Purpura (ITP) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Flebogamma DIF is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adults and children aged =2 years and primary immunodeficiency (PI) in adults. GamaSTAN S/D is prepared by cold ethanol fractionation from human plasma. GamaSTAN S/D and Igamplia is used for the prophylaxis of rubella, measles, varicella and hepatitis A. Flebogamma DIF and Gammunex injection solution are administered via intravenous route of administration. GamaSTAN S/D and Igamplia are administered by intramuscular route of administration.The drug candidate is also under development for the treatment of immune-mediated necrotizing myopathy, Coronavirus disease 2019 (COVID-19), postural tachycardia syndrome, Alzheimer’s disease, primary immunedeficiency disease, post-polio syndrome. The drug candidate was also under development for the treatment of cutaneous lupus erythematosus, relapsing remitting multiple sclerosis, epilepsy, myasthenia gravis, stiff-person syndrome and occult choroidal neovascularization.it was also under development for treatment induced neuropathy of diabetes.
Report Coverage
GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
Quick View – NPV Data | |||
Drug Name |
|
||
Administration Pathway |
|
||
Therapeutic Areas | |||
Key Manufacturers |
|
||
Drug Development Status |
|
Reasons to Buy
- Better understand the quantitative value of a specific drug
- Create or support internal NPV models to improve accuracy
- Understand the profit a drug is expected to make, taking into account revenue and cost forecasts leveraging public and proprietary data sets.
Frequently asked questions
- All drug sales and forecasts within NPV Model are calculated in our proprietary company based models . In these models, Analyst Consensus forecasts are built by using company-specific broker reports to create the sales forecasts for each Drug and Segment.
- Sales and forecasts are not indication-specific where drugs are approved , or in development, for multiple indications. Please refer to GlobalData’s Disease Analysis reports for indication-specific sales forecasts.
- Risk-adjusted NPVs use GlobalData’s LoA and PTSR for the indication in the highest development stage. Please refer to the Likelihood of Approval methodology for more details on this content.
GlobalData’s NPV Model is a premium model providing a fully-interactive forecasting and valuation tool, driven by Analyst Consensus estimates, enabling users to analyze and customize valuations for pharmaceutical assets including drugs or segments. The tool provides 17-year drug forecasts from companies with sales forecast data in the pharmaceutical industry, including established global firms and emerging biotechs, which allows access to critical information to facilitate strategic decision making around pharmaceutical assets
The NPV Model includes a forecasted Revenue Model, followed by a proprietary Patent Expiry Model, Operating Profit Model, Net Profit (apply Tax rate) and Discounted Cash Flow (apply Discount rates), to derive Net Present Value (NPV) for a chosen pharmaceutical asset
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.